mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Bogani, Costanza ^a   Bartalucci, Niccolò ^a   Martinelli, Serena ^a   Tozzi, Lorenzo ^a   Guglielmelli, Paola ^a   Bosi, Alberto ^a   Vannucchi, Alessandro M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; CYCLIN D1; ERYTHROPOIETIN; EVEROLIMUS; INC 424; PROTEIN BCL XL; PROTEIN KINASE PIM 1; RUXOLITINIB; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DIVISION; CELL PROLIFERATION; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; G1 PHASE CELL CYCLE CHECKPOINT; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; POLYCYTHEMIA VERA;

ANIMALS; ANTIGENS, CD34; CASE-CONTROL STUDIES; CELL LINE; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DRUG SYNERGISM; HEMATOPOIETIC STEM CELLS; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; JANUS KINASE 2; MICE; MUTATION; MYELOPROLIFERATIVE DISORDERS; PROTEIN KINASE INHIBITORS; PURINES; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84873138749     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054826     Document Type: Article

References (57)

1. Vannucchi AM, Guglielmelli P, Tefferi A, (2009) Advances in understanding and management of myeloproliferative neoplasms. AC- A Cancer Journal for Clinicians 59: 171-191.
2. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA, (2011) New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118: 1723-1735.
3. Levine RL, Pardanani A, Tefferi A, Gilliland DG, (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7: 673-683.
4. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, et al. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356: 459-468.
5. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, et al. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3: e270.
6. Beer PA, Campbell P, Scott LM, Bench AJ, Erber WN, et al. (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112: 141-149.
7. Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, et al. (2008) Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 112: 844-847.
8. Pardanani A, Guglielmelli P, Lasho TL, Pancrazzi A, Finke CM, et al. (2011) Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia 25: 1834-1839.
9. Prchal JF, Axelrad AA, (1974) Letter: Bone-marrow responses in polycythemia vera. N Engl J Med 290: 1382.
10. Dupont S, Masse A, James C, Teyssandier I, Lecluse Y, et al. (2007) The JAK2 V617F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110: 1013-1021.
11. Li J, Spensberger D, Ahn JS, Anand S, Beer PA, et al. (2010) JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 116: 1528-1538.
12. Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, et al. (2010) Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17: 584-596.
13. Marty C, Lacout C, Martin A, Hasan S, Jacquot S, et al. (2010) Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 116: 783-787.
14. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, et al. (2006) Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107: 4274-4281.
15. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, et al. (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108: 1652-1660.
16. Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, et al. (2006) Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 1: e18.
17. Xing S, Ho WT, Zhao W, Ma J, Wang S, et al. (2008) Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 111: 5109-5117.
18. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, et al. (2008) Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111: 3931-3940.
19. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, et al. (2010) Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 115: 3589-3597.
20. Liu PC, Caulder E, Li J, Waeltz P, Margulis A, et al. (2009) Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity. Clin Cancer Res 15: 6891-6900.
21. Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, et al. (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115: 3109-3117.
22. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, et al. (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363: 1117-1127.
23. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, et al. (2011) Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. J Clin Oncol 29: 789-796.
24. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, et al. (2010) Durable Responses with the JAK1/JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU). ASH Annual Meeting Abstracts 116: 313-.
25. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, et al. (2012) A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. New England Journal of Medicine 366: 799-807.
26. Harrison C, Kiladjian J-J, Al-Ali HK, Gisslinger H, Waltzman R, et al. (2012) JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New England Journal of Medicine 366: 787-798.
27. Tefferi A, Vainchenker W, (2011) Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies. J Clin Oncol 29: 573-582.
28. Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, et al. (2009) Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 114: 5024-5033.
29. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148.
30. Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, et al. (2006) Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 66: 11156-11165.
31. Engelman JA, Luo J, Cantley LC, (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619.
32. Engelman JA, (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
33. Maruani DM, Spiegel TN, Harris EN, Shachter AS, Unger HA, et al. (2012) Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation. Oncogene.
34. Kim D-H, Sarbassov DD, Ali SM, King JE, Latek RR, et al. (2002) mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery. Cell 110: 163-175.
35. Kim D-H, Sarbassov DD, Ali SM, Latek RR, Guntur KVP, et al. (2003) G[beta]L, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and mTOR. Molecular Cell 11: 895-904.
36. Feldman ME, (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38.
37. Janes MR, Limon JJ, So L, Chen J, Lim RJ, et al. (2010) Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16: 205-213.
38. Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, et al. (2008) Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 22: 87-95.
39. Ghaffari S, Kitidis C, Zhao W, Marinkovic D, Fleming MD, et al. (2006) AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation. Blood 107: 1888-1891.
40. Zhao W, Kitidis C, Fleming MD, Lodish HF, Ghaffari S, (2006) Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. Blood 107: 907-915.
41. Grimwade LF, Happerfield L, Tristram C, McIntosh G, Rees M, et al. (2009) Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. Br J Haematol 147: 495-506.
42. Drayer AL, Olthof SG, Vellenga E, (2006) Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors. Stem Cells 24: 105-114.
43. Ugo V, Marzac C, Teyssandier I, Larbret F, Lecluse Y, et al. (2004) Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 32: 179-187.
44. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, et al. (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16: 487-497.
45. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790.
46. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, et al. (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110: 1092-1097.
47. Vannucchi AM, Pancrazzi A, Guglielmelli P, Di Lollo S, Bogani C, et al. (2005) Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Pathol 167: 849-858.
48. Chou T-C, (2010) Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Research 70: 440-446.
49. Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, et al. (2007) Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 35: 32-38.
50. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, et al. (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113: 6182-6192.
51. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, et al. (2011) Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. J Clin Oncol 29: 1356-1363.
52. Tefferi A, (2012) JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 119: 2721-2730.
53. Pardanani A, GotlIb J, Jamieson C, Cortes J, Talpaz M, et al. (2008) A phase I study of TG101348, an orally bioavailanble JAK-selective inhibitor, in patients with myelofibrosis. Blood 112: 97.
54. Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, et al. (2011) Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 118: 2069-2076.
55. Meric-Bernstam F, Gonzalez-Angulo AM, (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27: 2278-2287.
56. Li G, Wang Z, Miskimen KL, Xie XY, Tse W, (2009) Genetic and pharmacologic targeting of STAT5/Gab2/PI3K/mTOR signaling in a mouse myeloproliferative disease model. Blood 114: 3902A.
57. Li G, Miskimen KL, Wang Z, Xie XY, Tse W, et al. (2010) Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin. Leukemia 24: 1397-1405.